Daniel J Hughes
Overview
Explore the profile of Daniel J Hughes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
1145
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Josephides E, Smith D, Bille A, Patel A, Rush H, Dunn R, et al.
Clin Lung Cancer
. 2025 Feb;
PMID: 39915192
Background: Immune checkpoint inhibitors have improved survival in patients with non-small cell lung cancer (NSCLC). Whilst PD-L1 expression is a useful predictive biomarker, data on concordance of expression between primary...
2.
Hughes D, Subesinghe M, Taylor B, Bille A, Spicer J, Papa S, et al.
Radiology
. 2022 Jun;
304(2):246-264.
PMID: 35762888
Immunotherapy has transformed the treatment landscape of many cancers, with durable responses in disease previously associated with a poor prognosis. Patient selection remains a challenge, with predictive biomarkers an urgent...
3.
Varnai C, Palles C, Arnold R, Curley H, Purshouse K, Cheng V, et al.
JAMA Netw Open
. 2022 Feb;
5(2):e220130.
PMID: 35188551
Importance: Large cohorts of patients with active cancers and COVID-19 infection are needed to provide evidence of the association of recent cancer treatment and cancer type with COVID-19 mortality. Objective:...
4.
Oxley S, Achampong Y, Sambandan N, Hughes D, Thomas M, Lockley M, et al.
Acta Obstet Gynecol Scand
. 2021 Sep;
100(11):2091-2096.
PMID: 34486103
Introduction: Ovarian cancer is associated with a venous thromboembolism risk of at least 7.2% by 2 years from diagnosis, and although patients undergoing surgery benefit from routine thromboprophylaxis, those undergoing...
5.
Lee L, Cazier J, Starkey T, Briggs S, Arnold R, Bisht V, et al.
Lancet Oncol
. 2020 Aug;
21(10):1309-1316.
PMID: 32853557
Background: Patients with cancer are purported to have poor COVID-19 outcomes. However, cancer is a heterogeneous group of diseases, encompassing a spectrum of tumour subtypes. The aim of this study...
6.
Pickles O, Lee L, Starkey T, Freeman-Mills L, Olsson-Brown A, Cheng V, et al.
Br J Cancer
. 2020 Jun;
123(5):691-693.
PMID: 32546835
The rapid emergence of COVID-19 has sent shockwaves through healthcare systems globally, with cancer patients at increased risk. The interplay of the virus and host immune system has been implicated...
7.
Lee L, Cazier J, Angelis V, Arnold R, Bisht V, Campton N, et al.
Lancet
. 2020 Jun;
395(10241):1919-1926.
PMID: 32473682
Background: Individuals with cancer, particularly those who are receiving systemic anticancer treatments, have been postulated to be at increased risk of mortality from COVID-19. This conjecture has considerable effect on...
8.
Young K, Hughes D, Cunningham D, Starling N
Ther Adv Med Oncol
. 2018 Dec;
10:1758835918816281.
PMID: 30574212
Despite decades of research, pancreatic ductal adenocarcinoma (PDAC) continues to have the worst 5-year survival of any malignancy. With 338,000 new cases diagnosed and over 300,000 deaths per year globally...
9.
Cresswell F, Fisher M, Hughes D, Shaw S, Homer G, Hassan-Ibrahim M
Clin Infect Dis
. 2014 Oct;
60(2):263-6.
PMID: 25301216
Hepatitis C virus (HCV) is increasingly common among human immunodeficiency virus (HIV)-infected men who have sex with men. We evaluated the efficacy of HCV core antigen in diagnosing acute HCV...